Correlation Between Intravascular Platelet Aggregation in Tumors and Hypoxia-Inducible Factor 1 Alpha Expression in Epithelial Ovarian Cancer: Implications for Prognosis and Staging
1
Department of Obstetrics and Gynecology, School of Medicine, Daegu Catholic University, Daegu 42472, Republic of Korea
2
Department of Pathology, School of Medicine, Daegu Catholic University, Daegu 42472, Republic of Korea
*
Author to whom correspondence should be addressed.
Cancers 2025, 17(3), 345; https://doi.org/10.3390/cancers17030345
Submission received: 8 December 2024
/
Revised: 1 January 2025
/
Accepted: 17 January 2025
/
Published: 21 January 2025
(This article belongs to the Special Issue Biomarkers for Treatment Prediction, Prognosis and Early Detection of Gynecologic Cancer)
Simple Summary
This study investigates the association between intravascular platelet aggregation in tumors and the prognosis of patients with ovarian cancer, which is often diagnosed at an advanced stage. The findings suggest that intravascular platelet aggregation in tumors contributes to the formation of a hypoxic environment, which in turn promotes cancer progression, metastasis, and resistance to treatment, leading to poorer survival outcomes. This research has the potential to influence future approaches to managing ovarian carcinoma and improving patient outcomes.
Abstract
Background/Objectives: This study aimed to evaluate the association between intravascular platelet aggregation in tumors and ovarian carcinoma prognosis and investigate underlying mechanisms. Methods: A retrospective analysis was conducted on 144 patients with ovarian carcinoma. Immunohistochemical staining for CD42b, hypoxia-inducible factor-1α (HIF-1α), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) was performed using tissue microarrays to assess intravascular platelet aggregation. Staining grades ranged from 1 to 3 for CD42b (platelet aggregation or microthrombus) and 0 to 3 for HIF-1α, PDGF, and VEGF. Results: Among the patients, 25 (17.4%) had grade 1 (no platelet aggregation), 85 (59.0%) had grade 2 (platelet aggregation), and 34 (23.6%) had grade 3 (microthrombus). The grade of intravascular platelet aggregation in ovarian carcinoma was statistically significantly associated with a poor prognosis (p = 0.037). In addition, in patients with more advanced stages of ovarian cancer, higher levels of intravascular platelet aggregation were observed. Additional analysis revealed a correlation between platelet aggregation and HIF-1α expression (correlation coefficient = 0.226, p= 0.006), while PDGF and VEGF showed no significant correlations. Conclusions: Intravascular platelet aggregation in tumors is associated with advanced stages and poor prognosis in ovarian carcinoma. The results of our study suggest a potential association with hypoxia induced by intravascular platelet aggregation in ovarian carcinoma.
1. Introduction
Ovarian carcinoma has the highest mortality rate among gynecological cancers because it is usually diagnosed at an advanced stage. Treatment for ovarian carcinoma typically involves optimal debulking surgery and adjuvant therapy, with the approach determined by the cancer stage, tissue differentiation, the amount of residual tumor, and the presence of alleles associated with homologous recombination deficiency, including BRCA [1,2].
Although thrombocytosis is not specific to malignancy, the association between cancer and platelets has been assessed in various studies [3]. Many studies have reported that platelet aggregation occurs more frequently in association with cancer, and the incidence of thrombotic events increases with various cancers, including ovarian cancer [4]. In patients with ovarian carcinoma, especially clear cell carcinoma, the risk of pulmonary thromboembolism or venous thromboembolism is increased [5].
It is known that cancer cells can induce platelet aggregation, which is caused by crucial molecules or surface receptor molecules on the surface of cancer cells [6]. According to a previous study, platelet aggregation in tumor cells is associated with cancer progression and metastasis, leading to research on new platelet-targeted therapeutic strategies [7]. Based on this background, we hypothesized that intravascular platelet aggregation in tumors may induce occlusion of tumor microvessels and hypoxia of the cancer microenvironment in patients with ovarian carcinoma. As a result, cancer cells are subjected to hypoxic stress, which is associated with proliferation, metastasis, and chemoresistance, which may be associated with a poor prognosis.
However, no association between intravascular platelet aggregation in tumors and prognosis in patients with ovarian carcinoma has yet been reported, and the underlying mechanisms have not been thoroughly elucidated. Therefore, the purpose of this study was to investigate the association between intravascular platelet aggregation in tumors and the prognosis of patients with ovarian carcinoma, along with the underlying mechanisms of this relationship.
2. Materials and Methods
2.1. Enrolled Patients
We identified patients with ovarian carcinoma who underwent staging surgery, with or without adjuvant chemotherapy, from the gynecologic oncology database managed by the Department of Obstetrics and Gynecology at Daegu Catholic University Hospital. A retrospective review of medical records was conducted for each patient. The inclusion criteria for the patients were as follows: (1) patients with epithelial ovarian cancer, including serous, mucinous, clear cell, and endometrioid histopathological types; (2) patients who received primary treatment at the institution; and (3) patients diagnosed between March 2000 and October 2010. Patients with transitional cell carcinoma, malignant Brenner tumors, or carcinosarcomas were excluded. Additionally, patients treated with neoadjuvant chemotherapy before primary debulking surgery were also excluded. This retrospective study was approved by the institutional review board (IRB) of our medical center (IRB approval number: CR-21-089, 16 June 2021). Based on the above criteria, a total of 144 patients with ovarian carcinoma were enrolled in the study.
2.2. Construction of Tissue Microarrays (TMA)
Before the samples were prepared for tissue microarrays (TMA), representative paraffin tumor blocks were selected based on the initial evaluation of hematoxylin and eosin (H&E)-stained slides of ovarian carcinoma tissues. Two tumor tissue cores (2 mm in diameter) were extracted from each donor ovarian carcinoma block using a manual punch arrayer (Quick-Ray, Uni-Tech Science, Seoul, Republic of Korea). These cores were placed into a new recipient paraffin block, which ultimately contained 59–91 tissue cores. Multiple sections (5 µm thick) were cut from the TMA blocks and mounted onto microscope slides. The TMA H&E-stained sections were examined under a light microscope by a pathologist to verify the presence of representative tumor areas.
2.3. Immunohistochemical Staining (IHC)
Immunohistochemistry was performed on 5 µm thick TMA tissue sections using the Ventana BenchMark ULTRA (Ventana Medical Systems Inc., Tucson, AZ, USA) according to the manufacturer’s instructions. CD42b, also known as platelet glycoprotein1b alpha chain (GP1BA), is expressed on platelets and megakaryocytes [8]. Thus, an anti-CD42b antibody was used for IHC staining to identify platelet aggregation in ovarian carcinoma. The specimens were incubated with a primary rabbit anti-CD42b antibody (1:100; ab134087; Abcam, Cambridge, MA, USA). Subsequently, the sections were incubated with the following primary antibodies: anti-hypoxia-inducible factor-1α (HIF-1α, mouse monoclonal, 1:100, ab16066, Abcam, Cambridge, MA, USA), anti-vascular endothelial growth factor A (VEGF, mouse monoclonal, 1:100, ab1316, Abcam, Cambridge, MA, USA), and anti-platelet-derived growth factor B (PDGF, mouse monoclonal, 1:100, ab51869, Abcam, Cambridge, MA, USA).
2.4. Interpretation of the IHC
The stained slides were scanned using a virtual slide scanner (Aperio ScanScope slide scanner, Leica Biosystems, Nussloch, Germany), and the degree of staining of each tissue core was quantified. The IHC result was interpretated as positive for each antibody when the sample was stained brown. CD42b expression levels were graded by an expert pathologist on a scale of 1 to 3 based on intravascular platelet aggregation in ovarian carcinoma. The patients’ medical records were blinded during the assessment. The CD42b staining was graded as follows: grade 1, no intravascular platelet aggregation; grade 2, intravascular platelet aggregation in tumors; and grade 3, intravascular microthrombus in tumors.
HIF-1α, PDGF, and VEGF expression levels were graded on a scale of 0 to 3 based on cytoplasmic and membrane staining intensity and the proportion of positive tumor cells by an expert pathologist (one of our authors, Sun Jae Lee). The staining was graded as 0 if no malignant cells were stained, 1 if staining was weakly positive in <1/3 of malignant cells, 2 if staining was weakly positive in >2/3 of malignant cells or strongly positive in >1/3 of malignant cells, and 3 if staining was weakly positive in most malignant cells or strongly positive in >2/3 of malignant cells [9].
2.5. Definitions of Overall Survival
Overall survival (OS) was defined as the duration from the date of diagnosis to the date of death caused by ovarian carcinoma. Patients who were alive at the time of analysis were censored at their most recent follow-up.
2.6. Statistical Analysis
Variables between groups were compared using the chi-square test. Correlation analysis of categorical data was performed using Spearman’s correlation analysis. The OS was estimated using the Kaplan−Meier life-table method. Differences in survival rates were evaluated using log-rank tests. The p-values were obtained from two-sided tests, and statistical significance was set at p < 0.05. Statistical analysis was performed using SPSS ver. 21 (IBM Co., Armonk, NY, USA).
3. Results
The characteristics of the enrolled patients are summarized in Table 1. These include age, parity, menopause, preoperative platelet count, CA125, CA19-9, largest ovarian tumor diameter, tumor site, stage, pathologic type, presence of hypertension, diabetes mellitus, ascites, and pelvic and para-aortic lymph node metastasis. A total of 144 patients with ovarian carcinoma were included in this study. The number of patients in each ovarian carcinoma stage was as follows: stage I—51, stage II—35, stage III—68, and stage IV—11. Regarding histologic type, serous adenocarcinoma was the most common (43.8%), followed by mucinous adenocarcinoma (24.3%), endometrioid adenocarcinoma (19.4%), and clear cell carcinoma (12.5%).
The IHC staining grades for intravascular platelet aggregation in ovarian carcinoma were categorized into three grades: grade 1 staining was observed in 17.4% (n = 25) of patients, grade 2 in 59.0% (n = 85), and grade 3 in 23.6% (n = 23.6). The higher grades of IHC staining corresponded to greater degrees of intravascular platelet aggregation. Representative pathological photographs are presented in Figure 1.
The association between intravascular platelet aggregation grade and the clinicopathological characteristics of ovarian carcinoma is presented in Table 2. There was no statistically significant association between intravascular platelet aggregation grade and presence of bilaterality, ascites, involvement of pelvic and para-aortic lymph nodes, or pathologic type of ovarian carcinoma. Blood thrombocytosis and platinum chemotherapy responses were also not associated with platelet aggregation grade. However, in patients with more advanced stages of ovarian cancer, higher levels of platelet aggregation were observed in the blood vessels within the ovarian carcinoma tissue (p = 0.002, Spearman’s correlation analysis).
Table 3 presents the results of the Kaplan−Meier survival analysis conducted based on CD42b IHC staining grades. Univariate analysis was performed to evaluate the association between the clinicopathologic characteristics of patients with ovarian carcinoma and survival rates. The results showed that age, ascites, pelvic or para-aortic lymph node metastasis, stage, and grade of intravascular platelet aggregation of the tumor were statistically significantly related to prognosis. The grade of intravascular platelet aggregation in ovarian carcinoma was statistically significantly associated with a poor prognosis (p = 0.037).
Based on the results shown in Table 3, multivariate analysis was performed for age (≤50 vs. >50 years), the presence of ascites and pelvic or para-aortic lymph node metastasis, stage (I or II vs. III or IV), and intravascular platelet aggregation in tumors (grade 1 vs. grades 2 and 3) by using a Cox regression hazard model. Age and stage were identified as independent prognostic factors for the survival of patients with ovarian carcinoma, as follows: age ≤50 vs. >50 (adjusted HR 1.940, 95% CI 1.197–3.146, p = 0.007) and stage I or II vs. III or IV (adjusted HR 6.874, 95% CI 3.369–14.025, p < 0.001). However, the presence of ascites, pelvic or para-aortic lymph node metastasis, and intravascular platelet aggregation in tumors were not independent prognostic factors. This result was found even when intravascular platelet aggregation in tumors was analyzed as grade 1 or 2 vs. grade 3.
The results presented in Table 4 indicate that additional analyses were performed to investigate the mechanism underlying the association between intravascular platelet aggregation in tumors and survival. These analyses revealed a significant correlation between intravascular platelet aggregation in tumors and HIF-1α expression (correlation coefficient = 0.226, p = 0.006). PDGF and VEGF expression were also analyzed, but no significant correlations were observed for PDGF (correlation coefficient = 0.034, p = 0.686) or VEGF (correlation coefficient = 0.131, p = 0.116). Figure 2 presents representative results of IHC staining for HIF-1α, VEGF, and PDGF, illustrating the staining grades 0 to 3, which reflect varying expression levels in the tumor samples.
4. Discussion
The association between cancer and platelets has been consistently reported [3]. Thrombocytosis often arises as a reactive condition triggered by factors such as acute infection, tissue damage, chronic inflammation, surgery, iron deficiency, or the rebound effect after bone-marrow suppression. Although thrombocytosis is not specific to cancer, the association between platelets and cancer has been increasingly recognized. In patients without anemia or inflammation, thrombocytosis may indicate the presence of occult malignancies [10].
Cancer enhances thrombopoiesis in the liver, leading to increased platelet production in the bone marrow. The production of hepatic thrombopoietin and subsequent thrombocytosis is caused by elevated levels of thrombopoietin-inducing cytokines, such as interleukin-1 (IL-1), IL-3, IL-11, and tumor-derived IL-6, in tumor-host tissues [11]. In a mouse model, hepatic thrombopoietin synthesis is upregulated in response to tumor-derived IL-6 by the mechanism of paraneoplastic thrombocytosis [11]. Additionally, granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) also promote the production of platelets [12,13].
According to the results in Table 3, intravascular platelet aggregation in tumors is associated with poor prognosis in patients with ovarian carcinoma. Additionally, based on the results in Table 2, intravascular platelet aggregation in tumors was found to be associated with advanced stage in patients with ovarian carcinoma. This suggests that poor prognosis may also be associated with an advanced stage of ovarian carcinoma. However, according to the results of the multivariate analysis, intravascular platelet aggregation does not appear to be a direct survival factor in ovarian carcinoma. Based on these results, it is suggested that as the stage progresses, platelet aggregation within tumor blood vessels and subsequent exposure to hypoxia may impact prognosis. There are studies on the association between tumor platelet infiltration and the prognosis of patients with pancreatic and gastric cancers [14,15,16]. One study has shown that platelet aggregation induced by tumor cells protects tumor cells from tumor necrosis factor-α mediated cytotoxicity, which helps tumor cells evade the body’s immune system [17]. However, difference in prognosis may also possibly depend on the proangiogenic role of platelets in the tumor microenvironment [18].
Several studies have reported that thrombocytosis is associated with poor prognosis in various malignancies. However, some studies have found conflicting results, so the association between thrombocytosis and prognosis is currently uncertain [19,20,21,22,23]. According to previous studies, ovarian carcinoma and thrombocytosis are associated with more advanced forms of the disease and lower survival rates. It is known that in patients with various malignancies, the probability of thrombotic event is increased [24]. Approximately 10% to 15% of patients with malignancies developed cancer-related venous thromboembolism, deep vein thrombosis, or pulmonary thromboembolism [25,26]. This increased risk is attributed to hypercoagulability caused by platelet aggregation [4,6,27].
Cancer changes platelet behavior by triggering platelet granule release and modifying the platelet phenotype and RNA profile. In particular, cancer cells induce platelet aggregation, and this ability is correlated with increased potential for cancer-cell metastasis [6,28]. We hypothesized that platelet aggregation or microthrombus formation within blood vessels contributes to a hypoxic tumor microenvironment. Furthermore, hypoxic stress in cancer cells induced by platelet aggregation or microthrombus formation in intertumoral blood vessels may be associated with the prognosis of patients with ovarian carcinoma. A previous study reported that hypoxic stress leads to the secretion of hypoxia-inducible factors, including platelet-derived growth factor B, angiopoietin 2, angiopoietin-like 4, placental growth factor, and vascular endothelial growth factor [29]. These factors promote cancer-cell proliferation, metastasis, and chemoresistance, which can lead to a poor prognosis for patients. However, the mechanism underlying the association between intravascular platelet aggregation in tumors in ovarian carcinoma and poor prognosis is still unclear.
Based on the correlation between HIF-1α and intravascular platelet aggregation in tumors in this study, it can be suggested that intravascular platelet aggregation within tumors induces changes in the tumor microenvironment, promoting hypoxic damage within the tumor that may contribute to reduced survival rates in cancer patients [30,31]. Intravascular platelet aggregation within tumors has the potential to activate HIF-1α, which contributes to enhancing drug resistance by promoting cellular metabolic changes and inhibiting cell death [32]. Several previous studies have found that hypoxic stress is associated with chemoresistance and metastasis in cancer cells [33,34,35]. In other studies, HIF-1α inhibitors have also been reported as therapeutic targets for inhibiting tumor proliferation and malignancy [36,37]. Therefore, additional therapeutic approaches targeting HIF-1α or platelet aggregation may have the potential to improve the prognosis of patients with ovarian carcinoma.
This study has several limitations. First, as a retrospective study relying on previously collected data, it may lack consistency or completeness. Second, the patients included in this study were treated between 2000 and 2010, a relatively long time ago, which may reduce the applicability of our findings to the current treatment landscape. While updated data from more recently treated patients could provide additional insights, the shorter follow-up periods associated with these patients may make it hard to perform a comprehensive survival analysis. Furthermore, we tried to minimize confounding factors introduced by relatively recent treatment modalities, such as poly (ADP-ribose) polymerase inhibitors, which have significantly influenced patient outcomes. Finally, although our study results show a significant relationship between intravascular platelet aggregation and HIF-1α, the correlation is very weak. This suggests that in addition to the effects of hypoxic damage, other mechanisms may also have had an effect. Therefore, further studies are needed to understand the mechanisms underlying this study result.
5. Conclusions
In conclusion, intravascular platelet aggregation in tumors is associated with poor prognosis in patients with ovarian carcinoma. Based on the findings of this study, it can be suggested that hypoxic damage may induce intravascular platelet aggregation in tumors, which is associated with lower survival rates in patients with ovarian carcinoma. Further research will be needed to better understand the underlying mechanisms.
Author Contributions
Study concept and design, J.M.R. and Y.S.C.; acquisition of data, Y.Y.J.; analysis and interpretation of data, J.M.R. and S.-J.L.; drafting of the manuscript, J.M.R. and Y.S.C.; study supervision, Y.S.C. All authors have read and agreed to the published version of the manuscript.
Funding
This work was supported by research grants from Daegu Catholic University in 2022 (Funding number: 20223027).
Institutional Review Board Statement
The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Ethics Committee of Daegu Catholic University Hospital (approval number: CR-21-089, 16 June 2021).
Informed Consent Statement
The Institutional Review Boards of the hospitals approved this retrospective study, and the requirement to obtain informed consent was waived.
Data Availability Statement
Data are available from the corresponding authors upon reasonable requests.
Conflicts of Interest
The authors declare no conflicts of interest.
References
- Mirza, M.R.; Monk, B.J.; Herrstedt, J.; Oza, A.M.; Mahner, S.; Redondo, A.; Fabbro, M.; Ledermann, J.A.; Lorusso, D.; Vergote, I.; et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N. Engl. J. Med. 2016, 375, 2154–2164. [Google Scholar] [CrossRef] [PubMed]
- Pujade-Lauraine, E.; Ledermann, J.A.; Selle, F.; Gebski, V.; Penson, R.T.; Oza, A.M.; Korach, J.; Huzarski, T.; Poveda, A.; Pignata, S.; et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017, 18, 1274–1284. [Google Scholar] [CrossRef] [PubMed]
- Xu, X.R.; Yousef, G.M.; Ni, H. Cancer and platelet crosstalk: Opportunities and challenges for aspirin and other antiplatelet agents. Blood 2018, 131, 1777–1789. [Google Scholar] [CrossRef] [PubMed]
- Davis, R.B.; Theologides, A.; Kennedy, B.J. Comparative studies of blood coagulation and platelet aggregation in patients with cancer and nonmalignant diseases. Ann. Intern. Med. 1969, 71, 67–80. [Google Scholar] [CrossRef]
- Takasaki, K.; Miyamoto, M.; Takano, M.; Soyama, H.; Aoyama, T.; Matsuura, H.; Iwahashi, H.; Ishibashi, H.; Sakamoto, T.; Furuya, K. Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma. Int. J. Clin. Oncol. 2019, 24, 1273–1283. [Google Scholar] [CrossRef]
- Jurasz, P.; Alonso-Escolano, D.; Radomski, M.W. Platelet–cancer interactions: Mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br. J. Pharmacol. 2004, 143, 819–826. [Google Scholar] [CrossRef]
- Strasenburg, W.; Jozwicki, J.; Durslewicz, J.; Kuffel, B.; Kulczyk, M.P.; Kowalewski, A.; Grzanka, D.; Drewa, T.; Adamowicz, J. Tumor Cell-Induced Platelet Aggregation as an Emerging Therapeutic Target for Cancer Therapy. Front. Oncol. 2022, 12, 909767. [Google Scholar] [CrossRef]
- Clemetson, K.J.; Clemetson, J.M. Platelet GPIb-V-IX complex. Structure, function, physiology, and pathology. Semin. Thromb. Hemost. 1995, 21, 130–136. [Google Scholar] [CrossRef]
- Aeffner, F.; Wilson, K.; Martin, N.T.; Black, J.C.; Hendriks, C.L.L.; Bolon, B.; Rudmann, D.G.; Gianani, R.; Koegler, S.R.; Krueger, J.; et al. The Gold Standard Paradox in Digital Image Analysis: Manual Versus Automated Scoring as Ground Truth. Arch. Pathol. Lab. Med. 2017, 141, 1267–1275. [Google Scholar] [CrossRef]
- Levin, J.; Conley, C.L. Thrombocytosis Associated with Malignant Disease. Arch. Intern. Med. 1964, 114, 497–500. [Google Scholar] [CrossRef]
- Stone, R.L.; Nick, A.M.; McNeish, I.A.; Balkwill, F.; Han, H.D.; Bottsford-Miller, J.; Rupairmoole, R.; Armaiz-Pena, G.N.; Pecot, C.V.; Coward, J.; et al. Paraneoplastic thrombocytosis in ovarian cancer. N. Engl. J. Med. 2012, 366, 610–618. [Google Scholar] [CrossRef] [PubMed]
- Rafii, S.; Shapiro, F.; Pettengell, R.; Ferris, B.; Nachman, R.L.; Moore, M.A.; Asch, A.S. Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood 1995, 86, 3353–3363. [Google Scholar] [CrossRef] [PubMed]
- Suzuki, A.; Takahashi, T.; Nakamura, K.; Tsuyuoka, R.; Okuno, Y.; Enomoto, T.; Fukumoto, M.; Imura, H. Thrombocytosis in patients with tumors producing colony-stimulating factor. Blood 1992, 80, 2052–2059. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Zhang, M.; Zhou, T.; Zhao, S.; Su, Z.; Liu, X. Role of platelet infiltration as independent prognostic marker for gastric adenocarcinomas. J. Clin. Lab. Anal. 2020, 34, e23320. [Google Scholar] [CrossRef] [PubMed]
- Xu, S.S.; Xu, H.X.; Wang, W.Q.; Li, S.; Li, H.; Li, T.J.; Zhang, W.H.; Liu, L.; Yu, X.J. Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor. World J. Gastroenterol. 2019, 25, 6248–6257. [Google Scholar] [CrossRef]
- Zhang, S.R.; Yao, L.; Wang, W.Q.; Xu, J.Z.; Xu, H.X.; Jin, W.; Gao, H.L.; Wu, C.T.; Qi, Z.H.; Li, H.; et al. Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Ann. Surg. Oncol. 2018, 25, 3984–3993. [Google Scholar] [CrossRef]
- Philippe, C.; Philippe, B.; Fouqueray, B.; Perez, J.; Lebret, M.; Baud, L. Protection from tumor necrosis factor-mediated cytolysis by platelets. Am. J. Pathol. 1993, 143, 1713–1723. [Google Scholar]
- Filippelli, A.; Del Gaudio, C.; Simonis, V.; Ciccone, V.; Spini, A.; Donnini, S. Scoping Review on Platelets and Tumor Angiogenesis: Do We Need More Evidence or Better Analysis? Int. J. Mol. Sci. 2022, 23, 13401. [Google Scholar] [CrossRef]
- Ikeda, M.; Furukawa, H.; Imamura, H.; Shimizu, J.; Ishida, H.; Masutani, S.; Tatsuta, M.; Satomi, T. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann. Surg. Oncol. 2002, 9, 287–291. [Google Scholar] [CrossRef]
- Pedersen, L.M.; Milman, N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur. Respir. J. 1996, 9, 1826–1830. [Google Scholar] [CrossRef]
- Sasaki, K.; Kawai, K.; Tsuno, N.H.; Sunami, E.; Kitayama, J. Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J. Surg. 2012, 36, 192–200. [Google Scholar] [CrossRef]
- Taucher, S.; Salat, A.; Gnant, M.; Kwasny, W.; Mlineritsch, B.; Menzel, R.C.; Schmid, M.; Smola, M.G.; Stierer, M.; Tausch, C.; et al. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb. Haemost. 2003, 89, 1098–1106. [Google Scholar] [PubMed]
- Zeimet, A.G.; Marth, C.; Muller-Holzner, E.; Daxenbichler, G.; Dapunt, O. Significance of thrombocytosis in patients with epithelial ovarian cancer. Am. J. Obstet. Gynecol. 1994, 170, 549–554. [Google Scholar] [CrossRef]
- Caine, G.J.; Stonelake, P.S.; Lip, G.Y.; Kehoe, S.T. The hypercoagulable state of malignancy: Pathogenesis and current debate. Neoplasia 2002, 4, 465–473. [Google Scholar] [CrossRef] [PubMed]
- Meikle, C.K.; Kelly, C.A.; Garg, P.; Wuescher, L.M.; Ali, R.A.; Worth, R.G. Cancer and Thrombosis: The Platelet Perspective. Front. Cell Dev. Biol. 2016, 4, 147. [Google Scholar] [CrossRef] [PubMed]
- Schulman, S. How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. Blood 2017, 129, 3285–3293. [Google Scholar] [CrossRef]
- Rickles, F.R.; Falanga, A. Molecular basis for the relationship between thrombosis and cancer. Thromb. Res. 2001, 102, V215–V224. [Google Scholar] [CrossRef]
- Honn, K.V.; Tang, D.G.; Chen, Y.Q. Platelets and cancer metastasis: More than an epiphenomenon. Semin. Thromb. Hemost. 1992, 18, 392–415. [Google Scholar] [CrossRef]
- Semenza, G.L. Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene 2013, 32, 4057–4063. [Google Scholar] [CrossRef]
- Oncul, S.; Cho, M.S. Interactions between Platelets and Tumor Microenvironment Components in Ovarian Cancer and Their Implications for Treatment and Clinical Outcomes. Cancers 2023, 15, 1282. [Google Scholar] [CrossRef]
- Taneja, N.; Chauhan, A.; Kulshreshtha, R.; Singh, S. HIF-1 mediated metabolic reprogramming in cancer: Mechanisms and therapeutic implications. Life Sci. 2024, 352, 122890. [Google Scholar] [CrossRef] [PubMed]
- Li, J.Q.; Wu, X.; Gan, L.; Yang, X.L.; Miao, Z.H. Hypoxia induces universal but differential drug resistance and impairs anticancer mechanisms of 5-fluorouracil in hepatoma cells. Acta Pharmacol. Sin. 2017, 38, 1642–1654. [Google Scholar] [CrossRef] [PubMed]
- Yang, H.; Zhang, H.; Yang, Y.; Wang, X.; Deng, T.; Liu, R.; Ning, T.; Bai, M.; Li, H.; Zhu, K.; et al. Hypoxia induced exosomal circRNA promotes metastasis of Colorectal Cancer via targeting GEF-H1/RhoA axis. Theranostics 2020, 10, 8211–8226. [Google Scholar] [CrossRef] [PubMed]
- Correia, A.L.; Bissell, M.J. The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist. Updates 2012, 15, 39–49. [Google Scholar] [CrossRef]
- Saxena, K.; Jolly, M.K.; Balamurugan, K. Hypoxia, partial EMT and collective migration: Emerging culprits in metastasis. Transl. Oncol. 2020, 13, 100845. [Google Scholar] [CrossRef]
- Bhattarai, D.; Xu, X.; Lee, K. Hypoxia-inducible factor-1 (HIF-1) inhibitors from the last decade (2007 to 2016): A “structure-activity relationship” perspective. Med. Res. Rev. 2018, 38, 1404–1442. [Google Scholar] [CrossRef]
- Jensen, R.L.; Ragel, B.T.; Whang, K.; Gillespie, D. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J. Neurooncol. 2006, 78, 233–247. [Google Scholar] [CrossRef]
Figure 1.
Representative photos of intravascular platelet aggregation in tumors for each grade of CD42b immunohistochemical staining (×100). The staining was graded as follows: grade 1 (A), no intravascular platelet aggregation; grade 2 ((B), arrows), intravascular platelet aggregation in tumors; grade 3 ((C), arrowheads), intravascular microthrombus in tumors.
Figure 1.
Representative photos of intravascular platelet aggregation in tumors for each grade of CD42b immunohistochemical staining (×100). The staining was graded as follows: grade 1 (A), no intravascular platelet aggregation; grade 2 ((B), arrows), intravascular platelet aggregation in tumors; grade 3 ((C), arrowheads), intravascular microthrombus in tumors.
Figure 2.
Representative photos of each grade of hypoxia-inducible factor (HIF-1α), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) immunohistochemical staining (×200). The staining was graded as 0 if no malignant cells were stained, 1 if staining was weakly positive in <1/3 of malignant cells, 2 if staining was weakly positive in >2/3 of malignant cells or strongly positive in >1/3 of malignant cells, and 3 if staining was weakly positive in most malignant cells or strongly positive in >2/3 of malignant cells.
Figure 2.
Representative photos of each grade of hypoxia-inducible factor (HIF-1α), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) immunohistochemical staining (×200). The staining was graded as 0 if no malignant cells were stained, 1 if staining was weakly positive in <1/3 of malignant cells, 2 if staining was weakly positive in >2/3 of malignant cells or strongly positive in >1/3 of malignant cells, and 3 if staining was weakly positive in most malignant cells or strongly positive in >2/3 of malignant cells.
Table 1.
Characteristics of the enrolled patients with ovarian carcinoma in this study (n = 144).
| Characteristic | Value * |
|---|---|
| Age (year) | 50.1 ± 13.4 (15–78) |
| Parity | |
| Nulliparous | 18 (12.5%) |
| Primiparous | 15 (10.4%) |
| Multiparous | 111 (77.1%) |
| Menopause | |
| Positive | 66 (45.8%) |
| HTN | |
| Positive | 16 (11.1%) |
| DM | |
| Positive | 6 (4.2%) |
| Preoperative platelet (103/μL) | 292.9 ± 93.7 (50–557) |
| Preoperative CA125 (U/mL) | 733.6 ± 1197.3 (7.5–5000) |
| Preoperative CA19-9 (U/mL) | 191.2 ± 698.0 (1–5000) |
| Largest ovarian tumor diameter (cm) | 11.7 ± 6.9 (2–40) |
| Tumor site | |
| Unilateral | 71 (49.3%) |
| Bilateral | 73 (50.7%) |
| Ascites | |
| Absent | 33 (22.9%) |
| Present | 111 (77.1%) |
| Pelvic LN metastasis | |
| Negative | 105 (72.9%) |
| Positive | 39 (27.1%) |
| Paraaortic LN metastasis | |
| Negative | 99 (68.8%) |
| Positive | 45 (31.3%) |
| Stage | |
| I | 51 (35.4%) |
| II | 14 (9.7%) |
| III | 68 (47.2%) |
| IV | 11 (7.6%) |
| Pathologic type | |
| Serous adenocarcinoma | 63 (43.8%) |
| Mucinous adenocarcinoma | 35 (24.3%) |
| Endometrioid adenocarcinoma | 28 (19.4%) |
| Clear cell carcinoma | 18 (12.5%) |
* Values are presented as mean ± standard deviation (range) or number (%). Abbreviations: HTN; hypertension, DM; diabetes mellitus, LN; lymph node.
Table 2.
Association between grade of intravascular platelet aggregation in tumors and clinicopathologic characteristics of patients with ovarian carcinoma.
Table 2.
Association between grade of intravascular platelet aggregation in tumors and clinicopathologic characteristics of patients with ovarian carcinoma.
| Value | Number of | Grade 1 | Grade 2 | Grade 3 | p-Value |
|---|---|---|---|---|---|
| Patients | (n = 25) | (n = 85) | (n = 34) | ||
| Age (years) | |||||
| ≤50 | 79 | 16 | 51 | 12 | 0.030 |
| >50 | 65 | 9 | 34 | 12 | |
| Tumor site | |||||
| Unilateral | 71 | 12 | 44 | 15 | 0.745 |
| Bilateral | 73 | 13 | 41 | 19 | |
| Ascites | |||||
| Absent | 33 | 6 | 21 | 6 | 0.703 |
| Present | 111 | 19 | 64 | 28 | |
| Pelvic LN metastasis | |||||
| Negative | 105 | 19 | 64 | 22 | 0.467 |
| Positive | 39 | 6 | 21 | 12 | |
| PALN metastasis | |||||
| Negative | 99 | 17 | 60 | 22 | 0.819 |
| Positive | 45 | 8 | 25 | 12 | |
| Pathologic type | |||||
| Serous | 63 | 12 | 33 | 18 | 0.337 |
| Mucinous | 35 | 8 | 23 | 4 | |
| Endometrioid | 28 | 4 | 18 | 6 | |
| Clear cell | 18 | 1 | 11 | 6 | |
| Stage | |||||
| I | 51 | 12 | 35 | 4 | 0.002 * |
| II | 14 | 6 | 5 | 3 | |
| III | 68 | 6 | 39 | 23 | |
| IV | 11 | 1 | 6 | 4 | |
| Thrombocytosis + | |||||
| Negative | 135 | 25 | 78 | 32 | 0.325 |
| Positive | 9 | 0 | 7 | 2 | |
| CTx response | 80 # | ||||
| Platinum-sensitive | 66 | 10 | 38 | 18 | 0.451 |
| Platinum-resistant | 14 | 1 | 7 | 6 |
* Spearman’s correlation analysis and all other analyses were performed with a chi-square test. + Thrombocytosis was defined as 450 × 103/μL or higher. # From a total of 144 patients, 80 relapsed patients were found. Abbreviations: LN, lymph node; PALN, paraaortic lymph node; CTx, chemotherapy.
Table 3.
Univariate analysis of 5-year and 10-year overall survival according to clinicopathologic characteristics and corresponding p-values (n = 144).
Table 3.
Univariate analysis of 5-year and 10-year overall survival according to clinicopathologic characteristics and corresponding p-values (n = 144).
| Value (Number of Patients) | 5-Year OS | 10-Year OS | p-Value |
|---|---|---|---|
| Age | |||
| ≤50 (n = 79) | 68.4% | 67.1% | <0.001 |
| >50 (n = 65) | 38.5% | 33.8% | |
| Ascites | |||
| Absent (n = 33) | 81.8% | 81.8% | 0.001 |
| Present (n = 111) | 46.8% | 43.2% | |
| Pelvic LN metastasis | |||
| Negative (n = 105) | 62.9% | 60.0% | 0.001 |
| Positive (n = 39) | 33.3% | 30.8% | |
| Paraaortic LN metastasis | |||
| Negative (n = 99) | 62.2% | 60.6% | 0.001 |
| Positive (n = 45) | 33.3% | 30.8% | |
| Stage | |||
| I, II (n = 65) | 86.2% | 86.2% | <0.001 |
| III, IV (n = 79) | 29.1% | 24.1% | |
| Thrombocytosis | |||
| Negative (n = 135) | 55.6% | 52.6% | 0.421 |
| Positive (n = 9) | 44.4% | 44.4% | |
| Intravascular platelet aggregation in tumors | |||
| Grade 1 (n = 25) | 72.0% | 72.0% | 0.037 |
| Grade 2 (n = 85) | 55.3% | 52.9% | |
| Grade 3 (n = 34) | 41.2% | 38.2% |
Abbreviations: OS, overall survival; LN, lymph node.
Table 4.
Correlation between immunohistochemical staining grade for HIF-1α, VEGF, and PDGF and intravascular platelet aggregation in ovarian carcinoma (n = 144).
Table 4.
Correlation between immunohistochemical staining grade for HIF-1α, VEGF, and PDGF and intravascular platelet aggregation in ovarian carcinoma (n = 144).
| HIF-1α | PDGF | VEGF | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | |
| Intravascular | 0 | 13 | 8 | 3 | 1 | 4 | 5 | 15 | 1 | 2 | 10 | 8 | 5 |
| platelet aggregation | 1 | 41 | 30 | 14 | 0 | 17 | 35 | 27 | 6 | 9 | 28 | 40 | 8 |
| 2 | 10 | 8 | 13 | 3 | 4 | 11 | 14 | 5 | 1 | 8 | 18 | 7 | |
| Spearman’s correlation coefficient | 0.226 * | 0.034 | 0.131 | ||||||||||
| p-value | 0.006 | 0.686 | 0.116 | ||||||||||
The numbers in each cell of the table represent the number of patients corresponding to each level of intravascular platelet aggregation and expression of HIF-1α, PDGF, and VEGF. * The correlation coefficient between HIF-1α and intravascular platelet aggregation in ovarian carcinoma is 0.226, and the coefficient of determination (r2) is 0.051. Abbreviation: HIF, hypoxia-inducible factor; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Ryu, J.M.; Jeong, Y.Y.; Lee, S.-J.; Choi, Y.S. Correlation Between Intravascular Platelet Aggregation in Tumors and Hypoxia-Inducible Factor 1 Alpha Expression in Epithelial Ovarian Cancer: Implications for Prognosis and Staging. Cancers 2025, 17, 345. https://doi.org/10.3390/cancers17030345
AMA Style
Ryu JM, Jeong YY, Lee S-J, Choi YS. Correlation Between Intravascular Platelet Aggregation in Tumors and Hypoxia-Inducible Factor 1 Alpha Expression in Epithelial Ovarian Cancer: Implications for Prognosis and Staging. Cancers. 2025; 17(3):345. https://doi.org/10.3390/cancers17030345
Chicago/Turabian StyleRyu, Jung Min, Yoon Young Jeong, Sun-Jae Lee, and Youn Seok Choi. 2025. "Correlation Between Intravascular Platelet Aggregation in Tumors and Hypoxia-Inducible Factor 1 Alpha Expression in Epithelial Ovarian Cancer: Implications for Prognosis and Staging" Cancers 17, no. 3: 345. https://doi.org/10.3390/cancers17030345
APA StyleRyu, J. M., Jeong, Y. Y., Lee, S.-J., & Choi, Y. S. (2025). Correlation Between Intravascular Platelet Aggregation in Tumors and Hypoxia-Inducible Factor 1 Alpha Expression in Epithelial Ovarian Cancer: Implications for Prognosis and Staging. Cancers, 17(3), 345. https://doi.org/10.3390/cancers17030345
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
